

ODB Update

 **Latuda**[®]
(lurasidone hydrochloride)

Sunovion Pharmaceuticals Canada Inc. is pleased to inform you that as of March 29, 2018 all available dosage strengths of LATUDA[®] are now included on the Ontario Drug Benefit Formulary



as a General Benefit with the following therapeutic notes:

- For the management of the manifestations of schizophrenia after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
- Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.¹

Pills shown are not actual size. NOTE: LATUDA should be administered with food (at least 350 calories independent of fat content) and tablets should be taken whole, not crushed or cut.

LATUDA is indicated for the management of the manifestations of schizophrenia in adolescents (15-17 years) and adults.² Consult the Product Monograph at www.sunovion.ca/monographs/latuda.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-866-260-6291.

1. Ontario Drug Benefit Formulary/Comparative Drug Index: March 29, 2018.

2. LATUDA Product Monograph, August 1, 2017.

LATUDA[®], SUNOVION and  are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.

© 2018 Sunovion Pharmaceuticals Canada Inc. All rights reserved.